Ernst-guenter Afting, Director at Sorrento Therapeutics, Inc. (SRNE), bought 360,000 shares at $0.14 ($50K) on 2010-12-21, disclosed to the SEC on 2011-02-18.
Open-market purchase of $50k SRNE by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Something here stands out, but not much.